within Pharmacolibrary.Drugs.ATC.A;

model A10AC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 1.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.00023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Insulin lispro is a rapid-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus. It acts quickly to lower blood glucose levels and is typically administered immediately before meals. Insulin lispro is approved and widely used in current diabetic management, both for type 1 and type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single subcutaneous injection.</p><h4>References</h4><ol><li><p>Grant, M, et al., &amp; Baughman, R (2022). Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. <i>Clinical pharmacokinetics</i> 61(3) 413–422. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01084-0&quot;>10.1007/s40262-021-01084-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34773608/&quot;>https://pubmed.ncbi.nlm.nih.gov/34773608</a></p></li><li><p>Garhyan, P, et al., &amp; Dassau, E (2023). Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. <i>Journal of diabetes science and technology</i> 17(2) 274–282. DOI:<a href=&quot;https://doi.org/10.1177/19322968221145200&quot;>10.1177/19322968221145200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36575993/&quot;>https://pubmed.ncbi.nlm.nih.gov/36575993</a></p></li><li><p>Caparrotta, TM, &amp; Evans, M (2014). PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue. <i>Diabetes, obesity &amp; metabolism</i> 16(5) 388–395. DOI:<a href=&quot;https://doi.org/10.1111/dom.12196&quot;>10.1111/dom.12196</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23941279/&quot;>https://pubmed.ncbi.nlm.nih.gov/23941279</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10AC04;
